Key insights
- Exelixis (EXEL) stock reached an all-time high, driven by strong Q1 2026 earnings and revenue beats, and positive clinical trial data for Cabometyx in neuroendocrine tumors. A new collaboration with Merck for a colorectal cancer trial further boosts sentiment. The company's strong financial health and perceived undervaluation suggest continued positive momentum, though its direct impact on the broader US equity market is limited to the healthcare sector.
Exelixis Inc stock reached an all-time high of $52.98, marking a significant milestone for the biotechnology company. The stock currently trades at $53.11 with a market capitalization of $13.34 billion and an attractive P/E ratio of 17.08, while its PEG ratio of 0.42 suggests the shares are trading at a low price relative to near-term earnings growth. Over the past year, Exelixis has experienced a notable increase, with its stock price rising by 24.86%. This surge reflects investor confidence and positive market sentiment surrounding the company’s prospects and developments in its drug pipeline. As Exelixis continues to innovate and expand its offerings, the stock’s performance remains a focal point for stakeholders and market analysts alike. According to InvestingPro analysis, the company appears undervalued at current levels and boasts an "EXCELLENT" financial health score of 3.88, with 13 additional ProTips available to subscribers.
In other recent news, Exelixis Inc. reported strong financial results for the first quarter of 2026, exceeding both earnings and revenue expectations. The company posted an earnings per share of $0.87, beating the forecasted $0.77, and generated revenue of $611 million, slightly above the anticipated $608.95 million. Additionally, Exelixis announced a collaboration with Merck for a phase 3 trial targeting patients with resected stage II/III colorectal cancer. Under this agreement, Exelixis will sponsor the STELLAR-316 pivotal trial, while Merck will provide its subcutaneous anti-PD-1 therapy, KEYTRUDA QLEX. Furthermore, Exelixis presented promising data from the phase 3 CABINET trial at a recent oncology conference. The results demonstrated that Cabometyx significantly reduced the risk of disease progression or death in patients with both non-functional and functional advanced neuroendocrine tumors. These developments highlight the company’s ongoing efforts in advancing cancer treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for EXEL plus thousands of other stocks and find your next hidden gem with massive upside.